Boehringer Ingelheim USA Corporation

Asia Deal Watch: Kaken acquires Aadi subsidiary and cancer drug Fyarro. Other deals include Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome.

Boehringer Ingelheim and Eli Lilly's Jardiance may prevent worsening of diabetic eye disease in type 2 diabetes patients, per JAMA Ophthalmology. Analysis of over 80,000 patients showed Jardiance users had 22% lower risk of existing diabetic eye disease worsening compared to DPP4 inhibitor users. The study suggests Jardiance's potential benefit in managing diabetic retinopathy.

Rising ACR20 response rates in placebo arms of rheumatoid arthritis trials may be linked to global recruitment shifts, with recent trials including more patients from less affluent countries.

Durvalumab improved progression-free survival (PFS) over placebo in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC) after platinum-based chemoradiotherapy (CRT), with a 25% reduction in risk of disease progression or death. Subgroup analysis showed consistent PFS benefit regardless of CRT type, and a trend toward improved overall survival (OS) was observed. PACIFIC-5 supports consolidation immunotherapy after either concurrent or sequential CRT.

The schizophrenia market in 7MM is projected to grow at a 7.4% CAGR, from $8.4b in 2021 to $17b in 2031, driven by 11 late-stage pipeline products. These therapies are expected to capture 33.4% of the market share in 2031, with Cobenfy projected to be the top-selling drug by 2031, with $2.2b in sales. However, patent expirations of LAIs may slow growth, though new therapies will help counterbalance this.

Adjusting for principal components in genome-wide association studies can induce collider bias, especially in admixed populations where PCs may capture local genomic features instead of global ancestry. LD pruning is more effective than excluding high LD regions, but optimal parameters vary. Model-based ancestry inference may offer a better alternative in some cases. Careful pre-processing and checking of PCs are crucial to avoid spurious associations.

The schizophrenia market in 7MM is expected to grow at a CAGR of 7.4% from $8.4bn in 2021 to $17bn in 2031, driven by 11 late-stage pipeline products. These new products, with higher annual cost of therapy, will capture 33.4% of global sales in 2031. Cobenfy, approved in 2024, could become the top-selling drug with $2.2 billion sales in 2031. The US dominates the market due to a large patient population and high drug costs. Challenges include generic erosion of antipsychotic LAIs, but pipeline therapies will fuel market growth.

Boehringer Ingelheim received a positive EMA recommendation for Ofev's use in children and adolescents with progressive fibrosing ILDs. The recommendation could lead to the first approval of a therapy for these conditions in children. Ofev, a kinase inhibitor, generated $3.8bn in global sales for the company in 2023.

The global Acute Myeloid Leukemia Therapeutics Market is projected to grow at a CAGR of 13.4% during 2024-2032, driven by advances in targeted therapies and immunotherapies.

Analysis of 18,710 US MASH patients (mean follow-up 6.5 years) revealed higher mortality risks with metabolic factors like kidney disease and regional differences. 1,465 deaths (70% cardiovascular, 17% liver-related) were observed. eGFR < 60mL/min/1.73m2 and 3+ comorbidities increased mortality. Southern US had higher all-cause mortality (HR, 1.56). MASH patients with BMI ≥25 kg/m2 and type 2 diabetes had 31/1000 patient-years mortality, 5x higher than those without liver disease.